Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04053322
Title Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNICANCER
Indications

Her2-receptor negative breast cancer

Therapies

Durvalumab + Fulvestrant + Olaparib

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST